Atorlip 10 mg Research Overview
Atorlip 10 mg is a pharmaceutical preparation manufactured by Cipla containing atorvastatin calcium, a synthetic statin compound belonging to the HMG-CoA reductase inhibitor class. This medication represents one of the most extensively studied lipid-lowering agents in cardiovascular research, with atorvastatin serving as a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis. Research applications focus on examining its mechanisms of action in hepatic cholesterol regulation, pleiotropic effects on endothelial function, and anti-inflammatory properties observed in various experimental models.
Laboratory Research Applications
Researchers at Stroid UK Shop investigate atorvastatin’s multifaceted pharmacological profile in cardiovascular disease models, examining its effects on low-density lipoprotein cholesterol reduction, apolipoprotein B regulation, and triglyceride metabolism. Studies evaluate its pleiotropic mechanisms including nitric oxide bioavailability enhancement, C-reactive protein modulation, and matrix metalloproteinase inhibition. Comparative research explores differences between various statin formulations available in the atorvastatin and hypolipidemic drugs category. Scientists also examine potential interactions with other research compounds including selective androgen receptor modulators and peptide therapeutics in comprehensive metabolic studies.
Product Specifications
| Active Ingredient | Atorvastatin Calcium |
|---|---|
| Strength | 10 mg per tablet |
| Manufacturer | Cipla Limited |
| CAS Number | 134523-00-5 |
| Molecular Formula | C₃₃H₃₅FN₂O₅ |
| Molecular Weight | 558.64 g/mol |
| Storage | Room temperature, dry environment |
| Research Classification | HMG-CoA reductase inhibitor |
Research Compliance Statement
Atorlip 10 mg tablets are intended exclusively for in-vitro laboratory research purposes by qualified researchers in appropriate facilities. This pharmaceutical preparation is not intended for human consumption, clinical diagnosis, or therapeutic applications. Researchers must ensure compliance with relevant institutional guidelines and regulatory frameworks governing statin research protocols. All studies should be conducted under appropriate supervision with proper safety measures and documentation procedures in accordance with laboratory research standards.
